Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Vitamin D for ADT-Induced Bone Loss in Prostate Cancer
NCT05838716Phase 3Recruiting
- Sponsor
- University of Rochester
- Start
- Dec 2023
- Primary completion
- Apr 2029
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised trial of vitamin d in osteoporosis (2 arms), sponsored by University of Rochester. Primary endpoints: Reduction of bone mineral density (BMD) loss as measured at the total hip at 52 weeks, Reduction of bone mineral density (BMD) loss as measured at the femoral neck at 52 weeks and 2 more. Started Dec 2023; status: recruiting.
02
Drugs
vitamin d
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05838716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838716.